NCT04699188
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KRAS
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have advanced (metastatic or unresectable) solid tumors that express the KRAS G12C mutation
Exclusions: Patients with active brain metastases
https://ClinicalTrials.gov/show/NCT04699188